Allakos Management
Management criteria checks 3/4
Allakos' CEO is Robert Alexander, appointed in Apr 2017, has a tenure of 7.58 years. total yearly compensation is $6.30M, comprised of 12.8% salary and 87.2% bonuses, including company stock and options. directly owns 0.8% of the company’s shares, worth $623.71K. The average tenure of the management team and the board of directors is 3.6 years and 6.4 years respectively.
Key information
Robert Alexander
Chief executive officer
US$6.3m
Total compensation
| CEO salary percentage | 12.8% |
| CEO tenure | 7.6yrs |
| CEO ownership | 0.8% |
| Management average tenure | 3.6yrs |
| Board average tenure | 6.4yrs |
Recent management updates
Recent updates
Allakos Runs Up Into A Near-Term Catalyst
Nov 07We Think Allakos (NASDAQ:ALLK) Needs To Drive Business Growth Carefully
Aug 27
We're Keeping An Eye On Allakos' (NASDAQ:ALLK) Cash Burn Rate
May 05We're Keeping An Eye On Allakos' (NASDAQ:ALLK) Cash Burn Rate
Dec 01Companies Like Allakos (NASDAQ:ALLK) Are In A Position To Invest In Growth
Aug 03Allakos (NASDAQ:ALLK) Will Have To Spend Its Cash Wisely
Apr 20Is Allakos Inc. (NASDAQ:ALLK) Expensive For A Reason? A Look At Its Intrinsic Value
Jan 04Allakos: Potential For Comeback With Lirentelimab With 2 Indications
Oct 18Allakos prices ~$150M underwritten offering
Sep 19Allakos falls as lead asset offers mixed results in late-stage trial
Sep 09Allakos (NASDAQ:ALLK) Will Have To Spend Its Cash Wisely
Aug 06Will Allakos (NASDAQ:ALLK) Spend Its Cash Wisely?
Apr 22Allakos: Sad End To A Promising Asset
Dec 23We're Hopeful That Allakos (NASDAQ:ALLK) Will Use Its Cash Wisely
Dec 01We Think Allakos (NASDAQ:ALLK) Can Afford To Drive Business Growth
Aug 16Allakos: Upcoming Phase 3 Data Makes The Stock Interesting
Aug 06Allakos provides lirentelimab clinical trial enrollment updates, names new CMO
Jun 07We're Hopeful That Allakos (NASDAQ:ALLK) Will Use Its Cash Wisely
May 02Have Allakos Inc. (NASDAQ:ALLK) Insiders Been Selling Their Stock?
Mar 10Allakos Inc. (NASDAQ:ALLK) Insiders Have Been Selling
Jan 28
We're Interested To See How Allakos (NASDAQ:ALLK) Uses Its Cash Hoard To Grow
Dec 07Allakos EPS misses by $0.02
Nov 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$179m |
| Jun 30 2024 | n/a | n/a | -US$206m |
| Mar 31 2024 | n/a | n/a | -US$214m |
| Dec 31 2023 | US$6m | US$805k | -US$186m |
| Sep 30 2023 | n/a | n/a | -US$166m |
| Jun 30 2023 | n/a | n/a | -US$151m |
| Mar 31 2023 | n/a | n/a | -US$165m |
| Dec 31 2022 | US$7m | US$782k | -US$320m |
| Sep 30 2022 | n/a | n/a | -US$371m |
| Jun 30 2022 | n/a | n/a | -US$403m |
| Mar 31 2022 | n/a | n/a | -US$411m |
| Dec 31 2021 | US$11m | US$745k | -US$270m |
| Sep 30 2021 | n/a | n/a | -US$220m |
| Jun 30 2021 | n/a | n/a | -US$199m |
| Mar 31 2021 | n/a | n/a | -US$181m |
| Dec 31 2020 | US$14m | US$710k | -US$153m |
| Sep 30 2020 | n/a | n/a | -US$134m |
| Jun 30 2020 | n/a | n/a | -US$113m |
| Mar 31 2020 | n/a | n/a | -US$93m |
| Dec 31 2019 | US$13m | US$600k | -US$85m |
| Sep 30 2019 | n/a | n/a | -US$75m |
| Jun 30 2019 | n/a | n/a | -US$65m |
| Mar 31 2019 | n/a | n/a | -US$55m |
| Dec 31 2018 | US$8m | US$500k | -US$44m |
| Sep 30 2018 | n/a | n/a | -US$37m |
| Jun 30 2018 | n/a | n/a | -US$32m |
| Mar 31 2018 | n/a | n/a | -US$27m |
| Dec 31 2017 | US$1m | US$300k | -US$24m |
Compensation vs Market: Robert's total compensation ($USD6.30M) is above average for companies of similar size in the US market ($USD650.80K).
Compensation vs Earnings: Robert's compensation has been consistent with company performance over the past year.
CEO
Robert Alexander (54 yo)
7.6yrs
Tenure
US$6,299,426
Compensation
Dr. Robert Alexander, Ph D., had been an Independent Director of Allena Pharmaceuticals, Inc. since June 2016 until 2022. He has been the Chief Executive Officer of Allakos Inc. since April 2017 and served...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 7.6yrs | US$6.30m | 0.80% $ 623.7k | |
| President | 5.3yrs | US$4.27m | 0.34% $ 269.7k | |
| Chief Financial Officer | 3.6yrs | US$2.74m | no data | |
| Chief Technical Officer | 1.3yrs | no data | no data | |
| Chief Medical Officer | less than a year | no data | 0.32% $ 250.4k | |
| Director of Medical Affairs & Data Analytics | no data | no data | no data |
3.6yrs
Average Tenure
54yo
Average Age
Experienced Management: ALLK's management team is considered experienced (3.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 7.5yrs | US$6.30m | 0.80% $ 623.7k | |
| Independent Director | 7yrs | US$387.12k | 0% $ 0 | |
| Independent Director | 8.6yrs | US$387.12k | 0% $ 0 | |
| Independent Director | 1.3yrs | US$378.28k | 0% $ 0 | |
| Independent Director | 2.3yrs | US$372.12k | 0% $ 0 | |
| Independent Director | 6.4yrs | US$389.62k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 1.3yrs | US$732.48k | 0.043% $ 33.9k |
6.4yrs
Average Tenure
62yo
Average Age
Experienced Board: ALLK's board of directors are considered experienced (6.4 years average tenure).